Prophylactic Use of Pentoxifylline and Tocopherol to Prevent Osteoradionecrosis of the Jaw in Post-Radiation Oral and Oropharyngeal Cancer Patients.

Adepitan A. Owosho, John Gleysteen, Burton Wood, David Schwartz

Introduction

A.T. Still Jniversitv

FRSON HEALTHCAR

Osteoradionecrosis (ORN) of the jaw is a well-known complication of postradiated head and neck oncology patients. The major risk factor for the precipitation of ORN of the jaw in post-radiated head and neck oncology patients is an invasive dental procedure such as dental extraction, scaling and root planing, bone reduction surgery, and implant placement [1-3]. Post-radiated head and neck oncology patients are susceptible to developing dental caries, which results in unsalvageable teeth requiring dental extractions predisposing them to ORN.

ORN is an area of exposed necrotic bone in a previously irradiated area that does not heal over a period of 3-6 months [4]. The risk for ORN postinvasive dental procedure (IDP) in an irradiated head and neck oncology patient is lifelong [5.6]. ORN is considerably challenging to manage with no standard therapeutic approach.

The prophylactic strategies used to prevent or reduce the risk of ORN after an IDP in post-radiated head and neck cancer patients, have been the use of antibiotics prophylaxis, hyperbaric oxygen therapy, and pentoxifylline and tocopherol (PENTO) [7-9]. This study aims to report the outcome of the prophylactic use of PENTO in the prevention of ORN of the jaw after an IDP

Methods

Post-radiated oral and oropharyngeal oncology patients referred to the dental oncology clinic for oral surgical invasive care were prescribed pentoxifylline 400mg BID and tocopherol 400 IU BID for 2 weeks before IDP and for 6 weeks after IDP. The assessment endpoint was defined as 6 weeks post-IDP with the outcomes assessed using four categories which were determined by the area of exposed bone: complete healing; partial healing: no change: and progression.

The following information was collected: Age and gender of the patient, tumor type, primary tumor site, radiation dose to primary tumor site, the type of IDP, extracted tooth/teeth sites, and diagnoses of extracted teeth. IRB approvals from University of Tennessee Health Science Center and A. T. Still University.

Results

Case No	Gender	Age	Tumor Type	Tumor Site [laterality]	Radiation Dose to Primary Tumor / Chemotherapy (Yes/No)	Invasive Dental Procedure	Tooth/Teeth Diagnosis Prior to Extraction
1	м	69	SCC	Unknown primary (TXN2CM0)	70 Gy / (Yes)	Extraction (#27)	NP/SAP/NR
2	м	66	SCC	Tonsil (Oropharynx) [Right]	70 Gy / (Yes)	Extractions (#1 and #31)	RR / NR
3	м	77	SCC	Tonsil (Oropharynx) [Right]	70 Gy / (Yes)	Extractions (#5 - #9, #11, #12, #15, #22 - #24, #27 and #30)	SIP – NP / SAP / NR
4	м	48	SCC	Tonsil (Left)	70 Gy / (Yes)	Extraction (#20)	NP/SAP
5	м	69	SCC	Tonsil (Oropharynx) [Right]	70 Gy / (Yes)	Surgical removal of bilateral mandibular borry exostosis	
6	м	68	SCC	Tonsil (Oropharynx) [Right] & Face Parotid [Left]	70 Gy / (Yes) & Irradiated 70 Gy	Extractions (#7 - #10, #12, #14 and #21 - #28) and surgical removal of bilateral mandibular tori	SIP - NP / SAP / NR
7	F	62	SCC	Posterior wall of oropharynx	70 Gy / (Yes)	Surgical removal of posterior maxiliary bony projection	
8	м	56	SCC	Oral Tongue/Floor of Mouth	70 Gy / (Yes)	Extractions (#23 - #26)	SIP / SAP / NR
9	м	69	SCC	Base of Tongue (Oropharynx)	70 Gy / (Yes)	Extraction (#19)	SAP / NR
10	м	70	SCC	Ventral Tongue/Floor of Mouth (Oral Cavity) [Right]	70 Gy / (Yes)	Extractions (#24, #25, #26, and #30)	RR / SIP / SAP / NR
11	F	59	SCC	Tonsil (Oropharynx) [Right]	70 Gy / (Yes)	Extraction (#19)	RR / NR
12	м	75	ACC	Hard palate/Maxillary Sinus (Oral Cavity) [Left]	66 Gy / (No)	Extraction (#18 and #31)	NP / SAP
13	F	56	SCC	Hard and Soft Palate (Oral Cavity)	88 Gy (Yes)	Extraction of #4, #5, and #12	SIP / SAP - RR / NR
14	м	67	SCC	Base of Tongue	70 Gy (Yes)	Extraction of #14 and #15	RR / NR

Summary

Fourteen (11 males and 3 females; ages range from 48 - 77 years) postradiated (min: 70 Gv) oral and oropharyngeal oncology patients received IDP varying from extractions (n=48 teeth), surgical reduction of tori and bony exostoses. At the assessment endpoint, all patients had complete healing of all IDP sites.













Conclusions

The ORN rate at patient level (0/14) and individual tooth level (0/48) was 0%. The PENTO regimen appears effective in reducing or preventing ORN in these patients. Given its safety and costeffectiveness, the PENTO protocol should be adopted as a prophylactic measure for post-radiated head and neck oncology patients undergoing invasive dental procedures. We recommend conducting large prospective studies to further confirm these findings.

References

1. Laiolo C. Rupe C. Gioco G. Trojano G. Patini R. Petruzzi M. et al. Osteoradionecrosis of the Jaws Due to Teeth Extractions during and after Radiotherapy: A Systematic Review, Cancers (Basel), 2021;13(22), doi: 10.3390/cancers13225798 2. Kojima Y. Otsuru M. Hasegawa T. Ueda N. Kirita T. Yamada SI, et al, Risk factors for osteoradionecrosis of the jaw in patients

with oral or propharyngeal cancer. Verification of the effect of tooth extraction before radiotherapy using propensity score matching analysis. J Dent Sci. 2022;17(2):1024-9. doi: 10.1016/j.jds.2021.10.019.

3. Toneatti DJ, Graf RR, Burkhard JP, Schaller B. Survival of dental implants and occurrence of osteoradionecrosis in irradiated head and neck cancer patients: a systematic review and meta-analysis. Clin Oral Investig. 2021;25(10):5579-93. doi: 10.1007/s00784-021-04065-6.

4. Marx RE. Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg. 1983;41(5):283-8. doi: 10.1016/0278-2391(83)90294-x

5. Wahl MU. Osteoradionecrosis prevention myths. Int J Radiat Oncol Biol Phys. 2006;64(3):661-9. doi: 10.1016/j.ijrobp.2005.10.021. 6. Martos-Fernandez M, Saez-Barba M, Lopez-Lopez J, Estrugo-Devesa A, Balibrea-Del-Castillo JM, Bescos-Atin C, Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125(5):431-9. doi: 10.1016/j.oooo.2018.02.004.

7. Marx RE, Johnson RP, Kline SN, Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin. J Am Dent Assoc. 1985;111(1):49-54. doi: 10.14219/iada.archive.1985.0074.

8. Shaw RJ. Butterworth CJ. Silcocks P. Tesfave BT. Bickerstaff M. Jackson R. et al. HOPON (Hyperbaric Oxygen for the Prevention of Osteoradionecrosis): A Randomized Controlled Trial of Hyperbaric Oxygen to Prevent Osteoradionecrosis of the Irradiated Mandible After Dentoalveolar Surgery. Int J Radiat Oncol Biol Phys. 2019;104(3):530-9. doi: 10.1016/j.ijrobp.2019.02.044. 9. Patel V, Gadiwalla Y, Sassoon I, Sproat C, Kwok J, McGurk M. Prophylactic use of pentoxifylline and tocopherol in patients who require dental extractions after radiotherapy for cancer of the head and neck. Br J Oral Maxillofac Surg. 2016;54(5):547-50. doi: 10.1016/j.bjoms.2016.02.024.

